359 related articles for article (PubMed ID: 33411331)
21.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
22. ALK positively regulates MYCN activity through repression of HBP1 expression.
Claeys S; Denecker G; Durinck K; Decaesteker B; Mus LM; Loontiens S; Vanhauwaert S; Althoff K; Wigerup C; Bexell D; Dolman E; Henrich KO; Wehrmann L; Westerhout EM; Demoulin JB; Kumps C; Van Maerken T; Laureys G; Van Neste C; De Wilde B; De Wever O; Westermann F; Versteeg R; Molenaar JJ; Påhlman S; Schulte JH; De Preter K; Speleman F
Oncogene; 2019 Apr; 38(15):2690-2705. PubMed ID: 30538293
[TBL] [Abstract][Full Text] [Related]
23. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
Mus LM; Lambertz I; Claeys S; Kumps C; Van Loocke W; Van Neste C; Umapathy G; Vaapil M; Bartenhagen C; Laureys G; De Wever O; Bexell D; Fischer M; Hallberg B; Schulte J; De Wilde B; Durinck K; Denecker G; De Preter K; Speleman F
Sci Rep; 2020 Jan; 10(1):218. PubMed ID: 31937834
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
25. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
26. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
27. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
28. RNA N
Cheng J; Xu L; Deng L; Xue L; Meng Q; Wei F; Wang J
Sci Rep; 2020 Aug; 10(1):13624. PubMed ID: 32788584
[TBL] [Abstract][Full Text] [Related]
29. LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN.
Yang R; Liu N; Li T; Liu F; Zhang J; Zhao H; Zou L; He X
J Transl Med; 2023 Sep; 21(1):659. PubMed ID: 37741985
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
31. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract][Full Text] [Related]
32. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
33. Frequency and Prognostic Impact of
Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
[TBL] [Abstract][Full Text] [Related]
34. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
35. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract][Full Text] [Related]
36. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract][Full Text] [Related]
37. Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
[TBL] [Abstract][Full Text] [Related]
38. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
39. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
[TBL] [Abstract][Full Text] [Related]
40. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]